Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Focal Adhesion Kinase (FAK) signaling is implicated in cancer development and aggressiveness, making it a key therapeutic target.
• Existing reversible FAK inhibitors are in clinical trials, but irreversible inhibitors offer potential pharmacological advantages like enhanced potency and duration.
• The need for novel, effective FAK inhibitors drives research into covalent targeting strategies.

Purpose of the Study:

• To report the structure-guided development of the first highly potent and irreversible inhibitor targeting the FAK kinase.
• To evaluate the efficacy of this novel inhibitor in reducing FAK autophosphorylation in cancer cells.
• To elucidate the binding mode and confirm covalent interaction within the FAK ATP binding site.

Main Methods:

• Structure-guided drug design was employed to develop a novel irreversible FAK inhibitor.
• The inhibitor's potency was assessed by measuring the decrease in FAK autophosphorylation in squamous cell carcinoma models.
• Cocrystallography was used to determine the binding interaction of the inhibitor with the FAK kinase domain.

Main Results:

• The study successfully developed a highly potent and irreversible FAK inhibitor.
• The inhibitor demonstrated significant reduction of FAK autophosphorylation in squamous cell carcinoma.
• Cocrystal structure analysis confirmed the inhibitor's covalent linkage to Cys427 within the FAK ATP binding site.

Conclusions:

• This work presents the first potent, irreversible covalent inhibitor of FAK, achieved through structure-guided design.
• The developed inhibitor effectively targets FAK signaling, showing potential for treating FAK-driven cancers.
• The confirmed covalent mechanism and binding mode provide a foundation for further optimization of FAK-targeted covalent inhibitors.